Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 9/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 8/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.37 |
| ▸ | CDK2 | P24941 | 5/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.37 |
| ▸ | CDK9 | P50750 | 3/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163561 | 0.78 | ADORA2A (0.48) | ADORA2ANPC1RAB9ADYRK1ADYRK2 | |
| SCHEMBL2696311 | 0.76 | DOT1L (0.54) | ADORA2ASMN1; SMN2DYRK1ADYRK2DYRK1B | |
| SCHEMBL15562763 | 0.74 | ADORA2A (0.55) | ADORA2ANPC1RAB9ADYRK1ADYRK2 | |
| SCHEMBL3413202 | 0.74 | ADORA2A (0.55) | ADORA2ANPC1RAB9ATNF | |
| SCHEMBL3415847 | 0.73 | MET (0.39) | SMN1; SMN2DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL3413630 | 0.73 | MET (0.42) | NPC1RAB9ADYRK1ADYRK2DYRK1B | |
| SCHEMBL3409082 | 0.72 | MET (0.46) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL3415357 | 0.72 | MET (0.38) | NPC1RAB9ADYRK1ADYRK2DYRK1B | |
| SCHEMBL20570515 | 0.71 | CHRNA7 (0.47) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL430630 | 0.71 | TNF (0.50) | ADORA2ANPC1RAB9ASMN1; SMN2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | ADORA2A 995/4885CHRNA7 4253/4885NPC1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.